Abstract
The aim of this study was to evaluate the short-term prognostic value of early measurement of serum lipoprotein (a) [Lp(a)] levels in Chinese patients with type 2 diabetes (T2D) and acute ischemic stroke (AIS). The study population comprised 232 consecutive patients with an AIS diagnosis complicated with T2D. Functional outcome was obtained on month 3 according to the modified Rankin Scale (mRS). Unfavorable functional outcome was defined as a mRS score of 3 to 6 points. The prognostic value of Lp(a) at admission to predict the unfavorable functional outcome 3 months after stroke onset was compared with the National Institutes of Health Stroke Scale score and other known outcome predictors. The Lp(a) levels in those patients were obtained with a median value of 16.8 mg/dl (IQR, 9.5–34.4 mg/dl). At 3-month follow-up, an unfavorable functional outcome was found in 86 patients (37.1%). In multivariate models comparing the second (Q2), third, and fourth quartiles against the first quartile of Lp(a), concentrations of Lp(a) in Q2, Q3, and Q4 were associated with unfavorable outcome, and increased risk of unfavorable outcome by 42, 131, and 211%. Interestingly, an elevated Lp(a, > 30 mg/dl) was also associated with unfavorable outcome, and with adjusted OR of 2.25 (95% CI 1.39–3.68). The AUC was significantly increased by adding Lp(a) to established risk factors (difference, 0.041 [95% CI, 0.034–0.053]; P = 0.02). The addition of Lp(a) to established risk factors significantly improved net reclassification improvement and integrated discrimination improvement. Higher Lp(a) levels at admission were associated with increased risk of unfavorable functional outcome and might be useful in identifying stroke patients with T2D at risk for unfavorable functional outcome for early prevention strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arenillas JF, Molina CA, Chacón P, Rovira A, Montaner J, Coscojuela P, Sánchez E, Quintana M, Alvarez-Sabín J (2004) High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology 63(1):27–32. https://doi.org/10.1212/01.WNL.0000132637.30287.B4
Barre DE, Griscti O, Mizier-Barre KA, Hafez K (2005) Flaxseed oil and lipoprotein (a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia, Canada. J Oleo Sci 54(6):347–354. https://doi.org/10.5650/jos.54.347
Beheshtian A, Shitole SG, Segal AZ, Leifer D, Tracy RP, Rader DJ, Devereux RB, Kizer JR (2016) Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis 253:47–53. https://doi.org/10.1016/j.atherosclerosis.2016.08.013
Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V (1989) Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20(7):864–870. https://doi.org/10.1161/01.STR.20.7.864
Chopra R, Saramma JG, Mary J, Rebecca A (2007) Lipoprotein (a) as a risk factor for diabetic retinopathy in patients with type 2 diabetes mellitus. Indian J Ophthalmol 55(3):195–198. https://doi.org/10.4103/0301-4738.31939
Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, Ambrose JA, Fallon JT (1998) Lipoprotein (a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 32(7):2035–2042
Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R, Heart Protection Study Collaborative Group (2011) Lipoprotein (a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet 4(1):68–73
Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG (2014) Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 63(5):470–477. https://doi.org/10.1016/j.jacc.2013.09.038
Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Müller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Müller B, Christ-Crain M (2009) Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66(6):799–808. https://doi.org/10.1002/ana.21783
Lam TD, Lammers S, Munoz C, Tamayo A, Spence JD (2013) Diabetes, intracranial stenosis and microemboli in asymptomatic carotid stenosis. Can J Neurol Sci 40(2):177–181. https://doi.org/10.1017/S031716710001369X
Li SY, Gao Y, Ma WN, Wang HC, Zhou G, Guo WC, Liu YH (2014) The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population. Inflammation 37(3):686–693. https://doi.org/10.1007/s10753-013-9785-x
Li S, Bi P, Zhao W, Lian Y, Zhu H, Xu D, Ding J, Wang Q, Yin C (2017) Prognostic utility of fatty acid-binding protein 4 in patients with type 2 diabetes and acute ischemic stroke. Neurotox Res. https://doi.org/10.1007/s12640-017-9792-z
Marcovina SM, Kennedy H, Bittolo Bon G, Cazzolato G, Galli C, Casiglia E, Puato M, Pauletto P (1999) Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania—the Lugalawa Study. Arterioscler Thromb Vasc Biol 19(5):1250–1256. https://doi.org/10.1161/01.ATV.19.5.1250
Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, Steinhagen-Thiessen E, Endres M, Ebinger M (2015) Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 242(2):496–503. https://doi.org/10.1016/j.atherosclerosis.2015.08.021
Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2):157–172. https://doi.org/10.1002/sim.2929
Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U (1989) Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9(5):579–592. https://doi.org/10.1161/01.ATV.9.5.579
Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13(7):1894–1190. https://doi.org/10.1097/01.ASN.0000019900.87535.43
Solfrizzi V, Panza F, Colacicco AM, Capurso C, D'Introno A, Torres F, Baldassarre G, Capurso A (2002) Relation of lipoprotein (a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients ≥ 65 years of age (The Italian Longitudinal Study on Aging). Am J Cardiol 89(7):825–829. https://doi.org/10.1016/S0002-9149(02)02192-6
Song FY, Wu MH, Zhu LH, Zhang ZQ, Qi QD, Lou CL (2015) Elevated serum mannose-binding lectin levels are associated with poor outcome after acute ischemic stroke in patients with type 2 diabetes. Mol Neurobiol 52(3):1330–1340. https://doi.org/10.1007/s12035-014-8941-0
Spence JD (2010) The role of lipoprotein (a) in the formation of arterial plaques, stenoses and occlusions. Can J Cardiol 26(Suppl A):37A–40A
Spence JD, Koschinsky M (2012) Mechanisms of lipoprotein (a) pathogenicity: prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol 32(7):1550–1551. https://doi.org/10.1161/ATVBAHA.112.251306
Tu WJ, Liu H, Liu Q, Cao JL, Guo M (2017) Association between serum lipoprotein (a) and diabetic retinopathy in Han Chinese patients with type 2 diabetes. J Clin Endocrinol Metab 102(7):2525–2532. https://doi.org/10.1210/jc.2016-4015
Von Depka M, Nowka-Göttl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S (2000) Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96:3364–3368
Wang CB, Zong M, Lu SQ, Tian Z (2016) Plasma copeptin and functional outcome in patients with ischemic stroke and type 2 diabetes. J Diabetes Complicat 30(8):1532–1536. https://doi.org/10.1016/j.jdiacomp.2016.07.030
Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S (2014) Discrimination and net reclassification of cardiovascular risk with lipoprotein (a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64(9):851–860. https://doi.org/10.1016/j.jacc.2014.03.061
Ye Z, Haycock PC, Gurdasani D, Pomilla C, Boekholdt SM, Tsimikas S, Khaw KT, Wareham NJ, Sandhu MS, Forouhi NG (2014) The association between circulating lipoprotein (a) and type 2 diabetes: is it causal? Diabetes 63(1):332–342. https://doi.org/10.2337/db13-1144
Zhang W, Zhang XA (2014) Prognostic value of serum lipoprotein (a) levels in patients with acute ischemic stroke. Neuroreport 25(4):262–266. https://doi.org/10.1097/WNR.0000000000000094
Acknowledgements
We are grateful to the Department of Neurology and Emergency Department; the nurses, physicians, and patients who participated in our study; and the staff of the central laboratory of the Hospital.
Author information
Authors and Affiliations
Contributions
All authors have contributed significantly, and that all authors are in agreement with the content of the manuscript.
Corresponding author
Ethics declarations
The study was approved by the ethics committee of the First Affiliated Hospital of Xinxiang Medical University. The patients or their relatives gave written informed consents prior to entering the study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Wang, H., Zhao, J., Gui, Y. et al. Elevated Lipoprotein (a) and Risk of Poor Functional Outcome in Chinese Patients with Ischemic Stroke and Type 2 Diabetes. Neurotox Res 33, 868–875 (2018). https://doi.org/10.1007/s12640-017-9850-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-017-9850-6